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Abstract 26 
SIC and DRS are related proteins present in only four of the more than 200 Streptococcus pyogenes 27 
emm-types. These proteins inhibit complement mediated lysis and/or the activity of certain 28 
antimicrobial peptides. A gene encoding a homologue of these proteins, herein called DrsG, has 29 
been identified in the related bacterium Streptococcus dysgalactiae subsp equisimilis (SDSE).  Here 30 
we show that geographically dispersed isolates representing 14 of 50 emm-types examined possess 31 
variants of drsG. However not all isolates within the drsG-positive emm-types possess the gene.  32 
Sequence comparisons also reveal a high degree of conservation in different SDSE emm-types. To 33 
examine the biological activity of DrsG, recombinant versions of two major DrsG variants, DrsGS 34 
and DrsGL, were expressed and purified.  Western blot analysis using antisera raised to these 35 
proteins demonstrated both variants to be expressed and secreted into culture supernatant. Unlike 36 
SIC, but similar to DRS, DrsG does not inhibit complement mediated lysis. However, like both SIC 37 
and DRS, DrsG is a ligand of the cathelcidin LL-37 and is inhibitory to its bactericidal activity in in 38 
vitro assays. The greatest similarity between DrsG and DRS/SIC is found in the signal sequence at 39 
the amino terminus and proline rich domains in the C-terminal half of the protein. Conservation of 40 
prolines in this latter region also suggests these residues are important in the biology of this family 41 
of proteins.  This is the first report demonstrating the activity of an AMP inhibitory protein in 42 
SDSE. These results also suggest that inhibition of AMP activity is the primary function of this 43 
family of proteins. The acquisition of complement inhibitory activity of SIC may reflect its 44 
continuing evolution.  45 
 46 
 47 
 48 
  49 
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Background 50 
Antimicrobial peptides (AMPs) are major components of the innate immune system that typically 51 
exert their antimicrobial activity via pore formation in the bacterial membrane.  Some AMPs are 52 
also reported to have chemotactic properties, recruiting immune cells such as monocytes, 53 
neutrophils and T-cells to the site of bacterial colonisation (1), or directly stimulate chemokine or 54 
cytokine secretion (2).  Active evasion or inhibition of AMP activity is therefore a strategy for the 55 
survival and multiplication of several pathogens that colonise the respiratory tract and skin (3). 56 
Streptococcus pyogenes (group A Streptococcus, GAS) and S. dysgalactiae subspecies equisimilis 57 
(human group C and G streptococci, SDSE) are related Gram-positive bacteria that colonise the 58 
skin and throat. Even though S. pyogenes is much more virulent than SDSE, both must contend with 59 
the innate immune system at these sites.  Some strains of S. pyogenes express related secretory 60 
proteins called SIC and DRS.  SIC is found in only two S. pyogenes emm-types, emm1 and emm57, 61 
and was first reported as a ligand for the complement proteins C6 and C7, inhibiting the formation 62 
of the membrane attack complex, thereby blocking complement mediated lysis of bacteria (4, 5). 63 
SIC was subsequently shown to inhibit the antimicrobial activity of numerous AMPs and proteins 64 
including LL-37, lysozyme, secretory leukocyte proteinase inhibitor (SLPI) and human α and β 65 
defensins (6, 7).  Additionally SIC is inhibitory to the antimicrobial activity of several chemokines 66 
which are secreted on the pharyngeal epithelial surface (8). DRS is a variant of SIC present in 67 
emm12 and emm55 GAS (9). The greatest homology between the two proteins is found in their 68 
proline-rich region (PRR) (10). While DRS is a ligand of C6 and C7, this binding does not inhibit 69 
complement function (9). DRS-SLPI interactions also do not prevent SLPI from killing M12 GAS. 70 
However, DRS binding to hβD-2 and hβD-3 and LL-37 abrogates their antibacterial activity.    71 
DNA encoding an orthologue of sic, previously called sicG, has been described in SDSE (11). 72 
Indeed microarray screening of several SDSE strains revealed a possible presence of a SIC-like 73 
gene in some SDSE isolates (12). However, as similarity between SicG and DRS is more 74 
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pronounced than that between SicG and SIC, in this manuscript we rename the protein and its gene 75 
as DrsG and drsG, respectively. Here we report that DrsG is a highly conserved secretory protein, 76 
with variation principally occurring due to the presence of one or more repeat domains. DrsG does 77 
not inhibit complement mediated lysis of sheep red blood cells. However DrsG does bind to LL-37, 78 
thereby inhibiting its bactericidal activity. The fact that DrsG, DRS and SIC all have LL-37 79 
inhibitory activity, suggests that this is the primary function of this family of proteins. Finally, we 80 
show that many SDSE emm-types contain isolates that harbor drsG. Unlike in GAS, not all isolates 81 
in these SDSE emm-types possess drsG. The highly conserved nature of DrsG and its inconsistent 82 
distribution within isolates of an emm-type suggests prolific acquisition of the gene through lateral 83 
gene transfers in SDSE lineages.  84 
 85 
Methods 86 
Bacterial Strains and growth conditions. The clinical isolates SDSE MD128 (stg93464), MD985 87 
(stc1400), MD604 (stc1400), MD03 (stg2078) and GGS124 (stg480) were previously described 88 
(12, 13). Additional clinical SDSE isolates representing 50 emm-types which were used to 89 
determine the distribution of drsG were described earlier (14-18). Unless otherwise specified SDSE 90 
and S. pyogenes were grown in Todd Hewitt Broth (THB), Todd Hewitt Agar (Oxoid) or Columbia 91 
Agar (CBA, Oxoid) supplemented with 5% defibrinated Horse Blood. Escherichia coli was grown 92 
on LB media supplemented with ampicillin (100µg.ml-1) where appropriate.  93 
 94 
Detection of drsG in SDSE. The presence of drsG in the genome of multiple SDSE isolates was 95 
determined using a combination of PCR, Southern hybridization and interrogation of draft SDSE 96 
genome sequences. PCR was performed using GoTaq® Green Master Mix (Promega) following 97 
manufacturers recommendations. Sicn2F (5’-GGAGGTCACAAACTAAGCAA-3’) and Sicc3R 98 
(5’-TGCCTATAGAAGGCACAACT-3’) are located upstream and downstream of drsG 99 
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respectively. Sicn1F (5’-AGTAAAACACTACTATTTACA-3’) and Sicc1R (5’-100 
AGTCATATGGCCAATCTT-3’) are complementary to internal drsG sequences (13). For Southern 101 
hybridization genomic DNA was digested to completion at 37oC for 3hrs with KpnI (New England 102 
Biolabs), electrophoresed on a 0.8% agarose gel then transferred to a nylon membrane (Amersham 103 
Biosciences) and probed with a digoxigenin dUTP labeled internal 250 base pair fragment of drsG. 104 
Following hybridisation the membranes were washed, blocked and incubated with anti-DIG 105 
alkaline phosphatase conjugated antibody (Roche Diagnostics) (1:20,000) prior to immunodetection 106 
with CDP-Star detection reagent (Tropix) and development (19). 107 
 108 
Bioinformatic analyses. Repeat sequences were identified using RADAR (20, 21). Pairwise and 109 
multiple alignments were conducted using NEEDLE and Clustal Omega (22) respectively. Putative 110 
signal sequences were detected using SignalP (23).   111 
 112 
Detection of DrsG in culture supernatants.  To supernatant from 20ml of bacterial culture,  2ml 113 
of 100% Trichloroacetic acid (TCA) was added and left on ice for 30 minutes. The precipitated 114 
proteins were collected by centrifugation (10000g/5min), washed in 10% TCA and dissolved in 115 
250µl of 0.1N NaOH. Total protein concentration was then determined using a BCA protein assay 116 
(Thermo Scientific). An aliquote of the protein solution was  electrophoresed in a SDS-PAGE gel, 117 
transferred to nitrocellulose, and probed with murine anti-DrsGL or DrsGS antisera followed by 118 
secondary goat anti-mouse IgG conjugated to horse radish peroxidase. The membranes were then 119 
immersed in ECL Plus chemilluminescence substrate (Amersham Biosciences) and exposed to x-120 
ray film.   121 
 122 
Protein expression and production of antisera. Codon optimised DNA encoding mature DrsG 123 
was cloned into the expression vector pJ404 by DNA2.0. The resulting plasmids were transformed 124 
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into E. coli Top10 cells, and the protein expression was induced by the addition of 1mM IPTG to 125 
the mid-log phase cultures. After a 3hr incubation, the pellets were lysed under native non-126 
denaturing conditions. Recombinant proteins were then purified using His-Trap HP 1ml columns 127 
(GE Healthcare Life Sciences). Antibodies to the two DrsG variants were produced in Quackenbush 128 
mice by immunising with the proteins emulsified in Complete Freunds Adjuvant, followed by 129 
boosts without adjuvant  on days 21 and 28 (24).         130 
 131 
Complement mediated lysis. Complement mediated lysis of sheep erythrocytes was performed as 132 
previously described (9). Briefly sheep erythrocytes (Applied Biological Products Management) 133 
were sensitised with hemolyisin (Virion) in gelatine veronal buffer (GVB++) for 30 minutes at 134 
37oC, followed by 30 minutes on ice. Human serum from human male AB plasma (Sigma-Aldrich), 135 
used as the complement source in these experiments, was titrated with sensitised sheep erythrocytes 136 
to determine the dilution that caused approximately 50% haemolysis of sheep erythrocytes. For the 137 
assay, 200pmol of protein (DrsGS, DrsGL or SIC) or PBS was pre-incubated with diluted human 138 
serum that resulted in 50% haemolysis for 10 minutes at 37oC. Hemolysin activated sheep 139 
erythrocytes (2.5x107 cells/well) were then added and incubated at 37oC for a further 15 minutes. 140 
Unlysed erythrocytes were removed by centrifugation at 400g for 10 minutes and haemolysis was 141 
measured by reading the absorbance of the supernatant at 415nm. Lysis of sheep erythrocytes with 142 
water was considered as 100% lysis. Statistical significance was determined using the unpaired t-143 
test.  144 
 145 
LL-37 binding to DrsG. Microtiter plates (LinBro PVC EIA plates, MP Biomedicals) were coated 146 
with 100µl of coating buffer (50mM carbonate coating buffer, pH 9.6) containing 10µg of DrsG or 147 
SIC, in triplicate. The plates were incubated overnight at 4°C, washed once in PBS-Tween20 148 
(PBST) and then blocked with PBST containing 5% skim milk powder for 1 hr at 37°C. Plates were 149 
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washed once using PBST and incubated (1h/37°C) with 10 µg of LL-37 in 0.5 % skim milk/PBST 150 
buffer. After washing, the binding of LL-37 was detected with primary rabbit anti-LL-37 IgG 151 
(1:5000; Osenses) and horseradish peroxidase labeled goat anti-rabbit secondary IgG (1:5000; 152 
Sigma). Wells in which LL-37, primary antibody or secondary antibody were omitted from the 153 
assay were used as controls. Reciprocal assays, in which LL-37 were used as the bound substrate, 154 
and free DrsG or SIC added were also performed.  155 
 156 
LL-37 survival assays. Survival assays were performed to assess the capacity of DrsG to inhibit 157 
LL-37 mediated killing of SDSE MD895 (drsG-negative). For these experiments 25µM LL-37 was 158 
preincubated with 25µM of either DrsG or SIC for 30min at 37°C in PBS. Mid-log phase SDSE 159 
MD985 was harvested and diluted to an OD600 of 0.1. Ten microlitres of the LL-37/protein mix was 160 
then added to 90µl of the bacterial culture and incubated at 37°C for a further 2.5 hrs. Serially 161 
diluted mixes were plated in duplicate onto Todd Hewitt agar and incubated overnight. The 162 
percentage CFU recovered was determined by comparing recovery in the absence and presence of 163 
LL-37. Data presented is the mean of three independent experiments each performed in duplicate. 164 
 165 
Results 166 
Distribution and conservation of DrsG in SDSE. PCR (Figure 1), Southern hybridization (Figure 167 
2) and examination of draft SDSE genome sequences resulted in identification of drsG in 30 of 193 168 
SDSE isolates (Table 1). Analysis of these sequences revealed the presence of two major variants. 169 
DrsGL (DrsG-large) encodes a 25 kDa protein that contains a putative signal sequence, and two 170 
repeat domains. The first repeat domain (RD1) is comprised of two repeat units, each of which also 171 
contains shorter internal repeat sequences (Figure 3).  The second repeat domain (RD2) includes 172 
two 12 amino acid repeating units separated by a spacer sequence. In contrast DrsGS (i.e. DrsG-173 
Small) lacks one of the repeat units in RD1, plus the amino acids between the first two repeat units. 174 
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Otherwise, DrsGS is 100% identical to DrsGL at the amino acid level. In total 23 isolates possessed 175 
drsGS and seven possessed drsGL. Of the 50 emm-types examined, 14 contained isolates that were 176 
drsG-positive (Table 2). However for some emm-types that represented by multiple isolates, not all 177 
isolates within these emm-types possessed drsG.  Isolates of the emm-types stc839, stc1400 and 178 
stg480 may contain either of these variants.  179 
 180 
Similarity between DrsG, DRS and SIC. DRS and SIC possesses a signal sequence, a short repeat 181 
region (SRR), proline rich region (PRR) and C-terminal domain (C-term). SIC additionally 182 
possesses a Long Repeat Region (LRR).  To identify the regions of identity between these protein 183 
and DrsGS, pairwise alignments using full length proteins were performed.  An relatively low 184 
overall identity of 34% and 22% was observed with DRS from GAS NS488 and SIC from GAS 185 
AP1 respectively, with the greatest identity in the signal sequence. When only amino acid 186 
represented overlapping sequences for the mature proteins were used, identity increased to 42% and 187 
33% respectively. On the basis of these observations we use the terminology DrsG to describe this 188 
protein in SDSE. Similar to DRS and SIC, the C-terminal region of DrsG contains an over-189 
representation of proline residues.   190 
 191 
DrsG is secretory protein. DRS and SIC in GAS are secretory products. As DrsGS and DrsGL 192 
also possess a similiar signal sequence we predicted that they would also be secreted by SDSE 193 
isolates positive to these genes. This was confirmed by Western blot analysis of TCA precipitated 194 
culture supernatants from both stationary and log-phase SDSE cultures (Figure 4).  After probing 195 
with DrsGL or DrsGS antibodies, bands at ~27kDa and ~24 kDa were observed in the culture 196 
supernatants of GGS124 (drsGL-positive) and MD604 (drsGS-positive), but were absent in the 197 
drsG-negative isolates, MD985 and MD128.   198 
 199 
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DrsG does not inhibit complement mediated lysis. DRS and SIC are known to bind to 200 
complement proteins, but only SIC inhibits complement mediated lysis. We therefore examined 201 
whether DrsGS and DrsGL had any inhibitory effect on complement function. To do so, sheep 202 
erythrocytes sensitised with haemolysin were incubated with equimolar concentrations of the 203 
recombinant proteins and human serum as a source of complement. Recombinant SIC showed 204 
significant inhibition of lysis of erythrocytes (37.3±1.5%, p=0.0005) when compared to PBS 205 
controls (no inhibition).  However neither DrsGL nor DrsGS showed inhibitory activity (Figure 5).  206 
 207 
DrsG is a ligand of LL-37. Indirect ELISAs were used to determine whether LL-37 was a ligand of 208 
DrsGS and DrsGL. Wellscoated with the recombinant proteins reacted with LL-37 and the binding 209 
was detected with anti-LL-37 antibodies and labeled secondary antibody. In contrast to the negative 210 
controls which lacked individual assay components, the optical density observed in experimental 211 
wells was significantly greater (Figure 6). In fact binding between LL-37 and DrsGS was the same 212 
as observed for LL-37 and SIC. However, when the reciprocal assays were performed where LL-37 213 
was bound to the plate, and free DrsG and anti-DrsG antibodies were used no binding between 214 
DrsG and LL-37 was observed. This equivocal result on physical binding required further 215 
experiments using biological activity as described below. 216 
 217 
Addition of DrsG increases the viability of SDSE in the presence of LL-37. To investigate 218 
whether interactions between DrsG and LL-37 as observed above inhibited the bactericidal activity 219 
of LL-37, SDSE MD985 (drsG-negative) was incubated in the presence of LL-37, DrsG  or LL-37 220 
pre-incubated with DrsG (Figure 7). LL-37 inhibited the growth of MD985 by 61% when compared 221 
to controls.   Pre-incubation of LL-37 with DrsGL, DrsGS or SIC, restored growth to 80% or 222 
greater. These results suggest that DrsG is capable of inhibiting the bactericidal activity of LL-37.    223 
 224 
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Discussion 225 
 LL-37 is an important AMP found in many parts of the human body. With relevance to the 226 
preferred tissue site of colonization of SDSE, LL-37 is expressed in both respiratory secretions and 227 
skin (2, 25). Inhibition of the activity of LL-37 would therefore be beneficial for SDSE colonization 228 
at these sites. Here we have demonstrated binding of DrsG and LL-37 when DrsG is used as the 229 
bound substrate in the ligand assays. However when the reciprocal experiment was performed with 230 
LL-37 as bound substrate, no interaction was observed.  A similar result was reported by Fernie-231 
King et al (6) for interactions between SIC and hβD-2. They suggested the difference between the 232 
two configurations of the assay was attributable to the masking of binding sites when a small 233 
molecule (i.e. hβD-2; 64 amino acids) was bound to a plate. Given the small size of LL-37 (37 234 
amino acids) a similar explanation could be applied.  Notwith standing this, the biological assay 235 
showed DrsG counteracted the bactericidal activity of LL-37 and provides clear support for  236 
DrsG/LL-37 interactions. 237 
 238 
In S. pyogenes, drs and sic are found in a restricted number of emm types (emm12 and 55, and 239 
emm1 and 57 respectively).  Within these emm-types drs and sic are universally found in all 240 
isolates. In contrast we found that although drsG was present in fourteen of 50 different SDSE 241 
emm-types tested, not all isolates from a drsG-positive emm-type possessed the gene. These results 242 
are in concordance with a recent publication by Oppegaard et el (26). When the results from this 243 
study are combined with results from two other distribution studies (13, 26), a total of 19 SDSE 244 
emm-types have now been identified as possessing isolates that harbor drsG. Thus the distribution 245 
of DrsG is widespread in SDSE, as defined by emm-type. The high conservation within isoforms 246 
(i.e DrsGL and DrsGS) in different emm-types, the inconsistent presence of drsG within emm-247 
types, and the fact that drsGS or drsGL can be found within the same emm-types are all indicative 248 
that the gene encoding DrsG is present on a mobile genetic element (MGE). Analysis of the DNA 249 
surrounding drsG in the draft genomic sequences used in this study found drsG to be predominantly 250 
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located between scpG and SDEG_0931 (11).  In one instance drsG assembled between scpG and a 251 
predicted transposase. With the exception of S. pyogenes emm57, the homologue of scpG in S. 252 
pyogenes, scpA, is also found adjacent to drs/sic. DNA encoding inactive genes associated with 253 
lateral gene transfer (LGT) is also present in this region in S. pyogenes (27, 28).   254 
 255 
Within the DrsGS variants conservation at the amino acid level is greater than 95%.  Similarly high 256 
levels of amino acid conservation are also present in DrsGL. Differences in the number of repeat 257 
unit in RD1 therefore represent the greatest level of diversity with DrsG. Conservation of DRS has 258 
also been reported in S. pyogenes (29). The conserved nature of DRS in the two species suggests 259 
that for isolates that acquire this gene, it plays an important biological role. This is in stark contrast 260 
to sic, where variation can be observed in epidemic waves (30) and suggests that although SIC and 261 
DRS/DrsG have similar ligands, their role in respective species may be different. Indeed, this is 262 
evident from the wide range of ligands and function for SIC and much restricted properties in DrsG.  263 
 264 
Proline rich C-terminal regions are a feature of SIC and DRS. Here we have extended this 265 
observation to DrsG. Whilst the proline rich regions of SIC and DRS are known to bind C6, C7, 266 
hβD-2 and hβD-3, the specific amino acids involved in the binding have not been elucidated. 267 
Proline-rich motifs have been identified as being important in many signaling and binding proteins 268 
(31) and there is a growing field of research investigating the binding capabilities and structural 269 
properties of proline rich domains. One such motif is the peptide ligand motif PxxP, where ‘x’ 270 
denotes any amino acid and it usually sits at the core of a proline rich domain sequence (32, 33). 271 
These domains are usually positioned towards the ends of a protein where they form extended 272 
structures that have been described as ‘sticky arms’ (34). Four such motifs are present in DrsG. 273 
DRS also contains four PxxP motifs and SIC six.  The prolines involved in these motifs are also 274 
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conserved between the three proteins.  Given the relatively low identity across the rest of the 275 
molecules, it is tempting to suggest that the PxxP motif plays a critical role in the binding of LL-37.     276 
 277 
Both commensals and pathogens have to overcome the antimicrobial properties of AMPs if they are 278 
to successfully colonise and persist on mucosal surfaces. Here we have shown that DrsG is 279 
conserved and protects SDSE from the antimicrobial activity of LL-37. Our results suggest that 280 
direct inhibition of the antimicrobial activity of LL-37 is an intrinsic property of these proteins.  281 
Given that multi-functional nature of both SIC and DRS it is also likely that DrsG may also inhibit 282 
other AMPs.  In doing so, we speculate that DrsG may give drsG-positive SDSE strains a selective 283 
advantage over drsG-negative SDSE in colonising and persisting in the throat.  284 
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Figure legends 
 
Figure 1. PCR detection of drsG in SDSE. Representative gels demonstrating amplification of 
drsG from SDSE chromosomal DNA using (A) internal and (B) external primer sets. The isolates 
and associated emm-type is depicted above the gel. Markers (kb) are shown on the left of the gel. 
Isolate and their respective emm-type are shown at the top of the figure.  
 
 
Figure 2. Chromosomal detection of drsG  in SDSE. Representative southern analysis of KpnI 
digested SDSE chromosomal DNA probed with a DIG dUTP labeled internal 250bp fragment of 
drsG. Molecular weight markers are shown on left.  
 
Figure 3. Figure 3. Schematic diagram showing the conserved repeat domain structure of DrsSGL, 
DrsGS, DRS and SIC. For DrGLs and DrsGS, the prolin rich sequences are found within RD2.  
Abbreviations: Signal Sequence (SS), Repeat Domain 1 (RD1), Repeat Domain 2 (RD2), Short 
Repeat Region (SRR), Proline Rich Region (PRR), Long Repeat Region  (LRR) and C-terminal 
region (C-term).  
 
Figure 4. DrsG is expressed and secreted by SDSE. (A) Western blot of concentrated culture 
supernatants from mid-log and stationary cultures of drsGL-positive GGS124 (lanes 1 and 2), drsG-
negative MD985 (lanes 3 and 4) and recombinant DrsGL (lane 5) probed with anti-DrsGL 
antibodies. (B) Western blot of concentrated culture supernatants from mid-log and stationary 
cultures of drsGS-positive MD604 (lanes 1 and 2 respectively), drsG-negative MD128 (lanes 3 and 
4 respectively) and recombinant DrsGS (lane 5) probed with anti-DrsGS antibodies. Molecular 
weight markers indicated on left. 
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Figure 5. DrsG does not inhibit complement mediates lysis of erythrocytes. DrsGL, DrsGS, SIC 
or PBS was pre-incubated with human serum. Sensitised sheep erythrocytes were then added and 
incubation continued for a further 30min. Unlysed erythrocytes were removed by centrifugation and 
haemolysis measured by measuring the absorbance of the supernatant at 415nm. Results are 
presented as inhibition of complement mediated lysis, where incubation of sheep erythrocytes with 
water was used the reference point for 100% lysis.  Data represent the mean of three independent 
experiments. Statistical significance was determined using the unpaired t-test.  
 
Figure 6. LL-37 interactions with DrsGL, DrsGS and SIC. Graphs on the left of each panel 
show the results when DrsGL, DrsGS or SIC were coated to the wells of a 96-well plate. LL-37 was 
added, followed by anti-LL-37 antibody, HRP-labelled secondary antibody and horse radish 
peroxidase.  Results for assays in which LL-37 (C1), LL-37 and primary antibody (C2) or 
secondary antibody (C3) were not added are included as controls. The graphs on the right of each 
panel represent the reciprocal assay in which LL-37 was used as bound substrate, and free DrsGL, 
DrsG or SIC added.  
  
Figure 7. Growth of SDSE in the presence of LL-37 and DrsG. SDSE MD985 (drsG-negative)  
was grown in the presence of LL-37 and/or DrsG/SIC. After a 2.5hr incubation, the bacteria were 
recovered, plated onto Todd-Hewitt agar and incubated overnight. The percentage growth, when 
compared to controls was determined for each individual assay.  The results presented are the mean 
of three independent experiments.   
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Table 1. DrsG-positive isolates are geographically distributed.  
Strain emmST Geographical origin DrsG variant 
NS4186 stC6979.0 Australia drsGS 
NS4760 stC6979.0 Australia drsGS 
NS3874 stC74a.0 Australia drsGS 
MR363962 stG2078 Portugal drsGS 
MR394314 stG2078 Portugal drsGS 
TK01 stg2078 Japan drsGS 
NCU133 stg2078 Japan drsGS 
6458-05 stG2078 USA drsGS 
3993-06 stG2078 USA drsGS 
3537-05 stG2078 USA drsGS 
MD03 stg2078 Australia drsGS 
GCS11ny stC839 India drsGL 
MR223754 stC839 Portugal drsGL 
MD504 stc839.0 Australia drsGS 
NS3975 stC839.0 Australia drsGS 
NS4722 stC839.2 Australia drsGS 
NS4599 stC839.2 Australia drsGS 
3878-06 emm57 USA drsGL 
8139-05 emm57 USA drsGL 
NCU21 stg62647 Japan drsGS 
GGS124 stg480 Japan drsGL 
KTS-1 stg480 Japan drsGS 
81-4 stg643 Japan drsGS 
6037-03 stG245 USA drsGS 
3442-04 stG3442 USA drsGS 
3122-05 stG485 USA drsGS 
3836-05 stG5063 USA drsGL 
8983-04 stC1400 USA drsGL 
MD604 stg1400 Australia drsGS 
MD10 stg6 Australia drsGS 
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Table 2. Distribution of drsGL and drsGS in SDSE. 
emmSTa drsG-positive 
isolates 
drsG-negative 
isolates 
DrsG variantb 
emm57 2 1 drsGL 
stC74a 1 10 drsGL 
stC839 6 3 drsGL (2); drsGs (4) 
stC1400 2 12 drsGL; drsGS 
stC6979 3 11 drsGS 
stG6 1 12 drsGS 
stG245 1 1 drsGL 
stG480 2 12 drsGL; drsGS 
stG485 1 3 drsGS 
stG643 1 7 drsGS 
stG2078 7 4 drsGS 
stG3442 1 0 drsGS 
stG5063 1 1 drsGL 
stG62647 1 3 drsGS 
a only results for emm-types with isolates possessing drsG are represented in the table.  
b numerals in brackets represent the number of isolates possessing drsGS or drsGL in the emm-type 
specified. 
 
 
